to adult smoking, alcohol use, hard drug use, physical aggression, and risky sexual behavior 1 ; frequent occurrences on police registers, repeated or serious crimes, and involvement in confrontational and destructive offenses 2 ; presence of generalized anxiety disorder (35%), social phobia (20%), obsessive-compulsive disorder (21%), depression (23%), bipolar disorder (46%), attention-deficit/hyperactivity disorder (ADHD; 62%), physical aggression, and substance abuse 3 ; and nonviolent offending and violent delinquency. 4 Thus, DBDs and aggressive behaviors are not only problematic at the time of first occurrence in the child's life, but they are also important early warning signs of potential deleterious consequences later in life. Therefore, evidence-based attempts to attenuate these problems early in life are clearly warranted.
Concomitant pharmacotherapy is increasing quickly in child and adolescent psychiatry, and this is especially the case for children with DBDs. For example, in a nationally representative sample of child psychiatric patients, 50% of children with ADHD and 61% of children with DBDs were taking combination pharmacotherapy. 5 In another nationally representative sample of 3,466 youth, subsuming 27,979 visits to U.S. physicians, the most commonly reported diagnostic categories were DBDs and ADHD (49%). 6 Multiclass prescriptions increased from 14% (1996) (1997) (1998) (1999) to 20% (2004-2007) of patient visits that included psychotropic medication (43% increase in combination therapy over 8 years). 6 When risperidone (RIS) was prescribed, concomitant psychotropic prescribing occurred 62% of the time. 6 The combination of ADHD medication plus antipsychotic medication was about 6 times more likely to occur than other multiclass combinations. Thus, augmented pharmacotherapy has become a fact of life in child psychiatry, despite the lack of controlled studies of combined pharmacotherapy. [5] [6] [7] One of the most contentious issues in the treatment of children with disruptive behavior problems is the increasing use of multiple concurrent medications, especially the addition of atypical antipsychotic agents, because little is known about the safety and efficacy of such regimens. 6 Aggressive behavior is one of the most prominent targets for the use of augmented pharmacotherapy in children. Of the medicines that have been assessed for managing aggression in youth, there is abundant evidence that psychostimulants, such as methylphenidate, can be helpful. 8, 9 This is not surprising given that ADHD and aggression often co-occur in children. Connor et al. 8 conducted a meta-analysis of 28 stimulant studies involving aggressive behavior in children with ADHD. They reported a wide range of effect sizes (ESs) for overt aggression (0.24-2.12, confidence interval 0.70-1.02). Furthermore, the presence of oppositional-defiant disorder (ODD) or conduct disorder (CD) led to significantly smaller ESs in managing overt aggression. This raises the possibility that DBDs may be linked to a decreased psychostimulant effect on aggression and poses the question of what to do when children show unsatisfactory psychostimulant response.
Risperidone has been shown consistently to decrease disruptive behavior in children. Findling et al. 10 reported less aggression after 10 weeks of RIS versus placebo (PBO) in 20 children with CD. Two large trials (N ¼ 110 and 118) of RIS in children with subaverage IQs (IQ <85) and high scores on the Conduct Problem subscale of the Nisonger Child Behavior Rating Form (NCBRF) showed highly significant decreases on the Conduct Problem subscale; an approximately 45% decrease accompanied RIS compared with an approximately 15% decrease with PBO. 11, 12 Large follow-up studies (N ¼ 107 and 504) showed maintained improvements over a year in previously medicated children, new gains in previously unmedicated children, and generally good tolerability (although weight gain was a problem for some). 13, 14 Hence, psychostimulants and atypical antipsychotics are a commonly used form of augmented pharmacotherapy, and each effectively decreases DBD symptoms. However, very little research has tested their combined efficacy despite their common joint use in the community for children with DBDs. In a pilot study of RIS versus PBO, Armenteros et al.
15 studied 25 children with ADHD and overt aggression; only children with affective/impulsive aggression were enrolled. They added RIS or PBO to constant doses of stimulants that were begun 3 weeks before study entrance. No significant differences in parent or teacher ratings of aggression were found after 4 weeks of combined RIS or PBO augmentation. Although the study reported a statistically significant difference in response rate (!30% improvement on the parent-rated aggression scale) favoring RIS, the authors' reanalysis of that finding was not statistically significant (Fisher exact test, p ¼ .22; Yates c 2 , p ¼ .24). It is possible that, with only 25 subjects, the study was underpowered.
Other studies of atypical antipsychotics added to stimulants have lacked proper controls. Kronenberger et al. 16 assessed the effects of open-label quetiapine over 9 weeks in 24 youth whose aggression was not adequately controlled after 3 weeks of Osmotic Release Oral System (OROS) methylphenidate. All measurements of aggression showed marked decreases from baseline (BL) to the end of methylphenidate monotherapy and further substantial statistically significant decreases when quetiapine was added. However, with this design, it is impossible to separate the effects of quetiapine alone from the PBO effect and the passage of time. Thus, there is a dearth of properly controlled and well-powered studies of combined stimulant and antipsychotic treatment in children with severe physical aggression and comorbid DBDs.
This study evaluated the contribution of RIS to the control of childhood DBDs (specifically CD or ODD) with severe aggression and comorbid ADHD when combined with ongoing psychostimulant (STIM) therapy and parent training (PT) in behavior management. PT was included because of its well-established efficacy in decreasing childhood disruptive behaviors, 17 particularly in combination with stimulant treatment in ADHD. 18 Thus, the design of the study was closely aligned with recommendations from an expert panel's Treatment Recommendations for Antipsychotics for Aggressive Youth (TRAAY). 19 An immediate decrease of DBD behaviors was predicted with initial stimulant treatment. Further, the combination of PT þ STIM þ RIS was predicted to produce significant improvement, exceeding that of PT þ STIM þ PBO.
METHOD Design
Because STIMs and PT are established treatments for ADHD and aggressive behavior, they were termed Basic treatment. The authors attempted to Augment these effects by adding RIS for half the participants. This was a 4-site, randomized, double-blinded, PBOcontrolled study of PT þ STIM (Basic treatment) compared with PT þ STIM þ RIS (called Augmented treatment hereafter) for the treatment of disruptive behavior in children with ADHD and ODD or CD. PT þ STIM was initiated at the end of the BL assessment. If subjects did not show a sufficient clinical response (defined below) at 3 weeks or if they showed deterioration at 4 to 6 weeks, the second agent (RIS or PBO) was added to the treatment package. Subjects were randomized in a 1:1 ratio at BL and the randomization was stratified by site and balanced for comorbid disruptive-disorder diagnosis (CD versus ODD) through a Web-based centralized randomization system. The clinical sites were The Ohio State University, Case Western Reserve University, the University of Pittsburgh, and Stony Brook University. More details regarding the background, methods, design, and variables are provided by Farmer et al.
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Ratings of global behavioral response were made by blinded evaluators who were not permitted to ask about adverse events (AEs) or to know treatment assignment. Primary clinicians rated AEs, made titration adjustments, and were responsible for breaking the blind if subjects, owing to nonresponse, exited study treatment at the end of the acute trial (9 weeks). During weeks 3 to 8, a clinical responder was defined a priori as having a blinded evaluator-determined Clinical Global Impressions-Improvement (CGI-I) score 20 of 1 (very much improved) and a parent-rated NCBRF-Typical IQ Disruptive Behavior total (NCBRF Disruptive-Total [DTotal]) score no higher than 15 (within 0.5 SD of the normative mean). 21 This stringent definition of responder was used to make sure that any youngster who had room for further improvement was given the chance to receive the second medication. This provided a rigorous test of the added value of combined pharmacotherapy and encouraged the ideal target of behavioral normalization, especially in the case of serious childhood aggression. For the purposes of statistical evaluation at study endpoint, a clinical responder was defined in the more usual way, as having a NCBRF D-Total decrease of at least 25% and a CGI-I of 1 (very much improved) or 2 (much improved).
Subjects
Inclusion criteria were as follows: 6 to 12 years of age, inclusive; DSM-IV DBD diagnosis (CD or ODD); DSM-IV diagnosis of ADHD (any subtype); evidence of serious physical aggression as rated on the Overt Aggression Scale-M 22 (score !3 on assaults against other people, objects, or self); and evidence of seriously disruptive behavior as determined by a parent or guardian rating of at least 27 (90th percentile) on the NCBRF D-Total. In addition, a CGI-Severity (CGI-S) score of at least 4 ("moderately ill" or higher) for aggression was required by blinded clinicians. Participants needed to be free of psychotropic medicines for 2 weeks for most drugs (such as most antidepressants, a-agonists, b-blockers, anxiolytics, mood stabilizers, oral antipsychotics, and antihistamines) and 4 weeks for depot antipsychotics or fluoxetine. This rule was occasionally relaxed (to as few as 3-7 days) for extreme cases who could not tolerate being unmedicated the full time, as approved by the cross-site steering committee.
Exclusion criteria included Full-Scale IQ below 71; pregnancy or a history of seizure disorder or other neurologic or medical disorder for which medication might present a considerable risk; abnormal liver function; pervasive developmental disorder, schizophrenia, other psychotic disorders, or eating disorders; hypomanic/biphasic score of at least 36 as rated by a child's parent on the General Behavior Inventory (see below) and, if positive, confirmed by clinician as an indication of mood disorder; current or previous major depressive disorder or diagnosis of bipolar disorder; current use of psychotropic medications from which discontinuation would present a significant risk; active substance use disorder; evidence of current child abuse or neglect; history of suicide attempt in the past year or current suicidal ideation; and family history of type 2 diabetes in at least 2 first-degree relatives (owing to potential weight gain with RIS).
The study was approved by the institutional review board of each investigative site; parents or guardians signed consent forms, and child participants gave assent before enrollment.
Procedure
Thereafter, families were involved in the following visits and assessments. A schedule of measurements appears in Farmer et al.
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Screening Visits. Screening visits occurred within 4 weeks of BL. During screening, the authors completed the physical examinations, conducted clinical laboratory tests and electrocardiography, and interviewed parents regarding the child's medical history. IQ was assessed with the Kaufman Brief Intelligence Test-2, 23 and clinicians interviewed child and parent using the Schedule for Affective Disorders and Schizophrenia for school-aged children 24 to establish the presence of ADHD and ODD or CD and to rule out bipolar disorder, schizophrenia, and other exclusionary conditions. Parents rated their children on the General Behavior Inventory 25 to ensure further that children with bipolar disorder were detected.
Clinicians completed the Overt Aggression ScaleModified, a 7-item instrument from parent and child reports. 22 Questions assess aggression on the dimensions of assaults against objects, others, and self on rating subscales ranging from 0 (no events) to 5 (severe events). Children receiving a score of at least 3 at screening and at BL qualified for inclusion. Providing some notion of initial severity, a score of 3 for assaults against objects is anchored with "breaks objects, smashes windows," whereas a score of 3 for assaults against others is characterized as "attacks others, causing mild injury (bruises, sprains, welts, etc.)."
Parents also rated their child on the NCBRFTypical IQ version (called NCBRF hereafter) at screening, BL, and weeks 3 through 9. 21 The NCBRF provides 1 prosocial subscale (Positive/Social) and 6 problem behavior subscales (Conduct Problem, Oppositional Behavior, Hyperactive, Inattentive, Overly Sensitive, and Withdrawn/Dysphoric). 21 The NCBRF has excellent internal consistency, distinguishes between controls and subjects with DBDs, and its predecessor (for children with developmental disabilities) was highly sensitive to drug effects. Conduct Problem and Oppositional Behavior subscales map closely to DSM-IV-TR symptoms of CD and ODD; they were scored together to form a variable called the D-Total. The D-Total was the primary outcome measure for this study. The Hyperactive and Inattentive subscale scores were combined to form a total ADHD score.
To qualify, a child also required a CGI-S 20 score of at least 4, reflecting the presence of consistent ADHD and disruptive and physically aggressive/ destructive behavior. Anger, defiance, and aggressive speech were not enough to qualify children for the study. Subjects had to display behavior that was physically harmful to others, themselves, or the environment around them. We established inter-rater reliability on the CGI-S and CGI-I subscales by discussion at investigator meetings, subsequent "gold standard" test vignettes, and repeated recertifications of blinded evaluators.
The subjects were assessed on the following safety measurements at screening and all visits thereafter: the Barnes Akathisia Scale, 26 a clinician-completed scale using objective observation/clinical judgment and the patient's subjective experience of restlessness; the Simpson-Angus Rating Scale, which checks for extrapyramidal side effects (rigidity, dystonia, and abnormal glabellar reflex) of antipsychotics 27 ; and the Abnormal Involuntary Movement Scale, 28 a standardized clinician-rated review of tremor, dyskinesia, and other possible antipsychotic neuromotor side effects.
BL and Subsequent Visits. At BL and thereafter, the following assessments were performed: vital signs, height, weight, open-ended elicited AEs, specific side effects ratings by parents and primary clinicians, and concomitant medications. The CGI-I was obtained at all visits, whereas the CGI-S was completed at end of weeks 3 and 9. Parents completed the Antisocial Behavior Scale (ABS) 29 at BL and week 9 or the endpoint. The 28-item ABS has a Proactive Aggression subscale (5 proactive items and 5 covert antisocial items) and a Reactive Aggression subscale (6 items). 29 This instrument was used to differentiate affective from proactive subtypes of aggression and to assess treatment effects on the 2 subtypes.
Beginning at BL, a 9-session course of PT was administered with up to 2 optional booster sessions using an empirically established program for children (the Community Parent Education Program [COPE]). 30 Fidelity was monitored through audio tapes, reviewed by the Pittsburgh site, and by regular conference calls. The COPE's focus on strategies for managing impulsive behavior, including reactive aggression, made it a good fit for this protocol.
From BL through week 3, primary clinicians openly titrated STIM medication to optimal effect by balancing benefits and side effects, usually in the form of OROS methylphenidate (Concerta, ALZA Corporation, Janssen Pharmaceuticals, Mountain View, CA). For smaller children (<25 kg), dosage was titrated clinically using the following daily doses: 18 mg (7 days), 36 mg, and 54 mg (maximum maintenance dose). For larger children (>25 kg), dosage was increased every 3 to 4 days using the following daily doses: 18, 36, 54, and 72 mg. 9 Subjects unable to tolerate OROS methylphenidate or unable to swallow pills were offered an alternative (at comparable doses) from the following, of which the capsule contents could be sprinkled onto food: mixed amphetamine salts (Adderall, Shire Pharmaceuticals, Dublin, Ireland), dextromethylphenidate extended release (Focalin XR, Novartis, Basel, Switzerland), or lis-dexamphetamine dimesylate (Vyvanse, Shire US, Dublin, Ireland).
If residual symptoms remained, then randomized PBO or RIS was added to treatment at weeks 4 through 6. For children weighing less than 25 kg, RIS was dosed at 0.5 to 2.5 mg/day; for children heavier than 25 kg, dosing ranged from 0.5 to 3.5 mg/day. 9 The RIS titration schemes allowed for dose increases every 3 to 7 days, following a schedule that specified maximum dose increases over 29 days of titration; doses could always be held constant or decreased if a satisfactory clinical response occurred or if indicated by AEs.
Statistical Analysis
Primary and Secondary Analyses. For the primary outcome, NCBRF D-Total score, a constrained longitudinal data analysis model, in which BL and post-BL values were treated as dependent variables, was used in the intention-to-treat (ITT) population (all randomized subjects). 31 The outcome was square root transformed to accommodate the assumption of normality. Fixed effects in the final model included those for time, group, time by group interaction, site, and disorder type. Other interaction effects, such as effects for site by time by group, site by time, and site by group, were explored and none of them was statistically significant. An unstructured variance covariance matrix was assumed for the correlated measurements within each subject. Empirically based sandwich estimators were obtained to assess the group differences at week 9. 32 Although mixed models can be used in the presence of missing data, the missing data at random assumption are not directly testable. Thus, various sensitivity analyses were conducted to examine the robustness of results. Secondary longitudinal outcome variables, such as subscales other than the D-Total of the NCBRF and weight, were modeled in a similar fashion to the D-Total. Dichotomous rates of response to treatments were compared between groups by Fisher exact tests. For the ABS Proactive and Reactive Aggression subscales rated by parents, BL and post-BL measurements were analyzed by the constrained longitudinal data analysis model with fixed effects for time, group, site, and disorder. Because their distribution was non-normal, prolactin levels were compared using the Wilcoxon ranked sum test. The secondary outcome variables were corrected for multiplicity by using Bonferroni corrections at the scale level Cohen's d was used to estimate ES; ES was calculated using complete cases, a subset of the ITT. All analyses were conducted in SAS 9.2 (SAS Institute, Cary, NC).
Power Analysis. With a 2-sided a of 0.05, there was 80% power to detect an ES of 0.5 with complete data from 128 subjects (64 per group). To allow for average attrition of 20%, the authors concluded that 160 patients (80 per group) were needed, although the ITT analysis included all subjects.
Data Management. The Data Coordinating Center used Teleform (HP Autonomy, Hewlett-Packard, Palo Alto, CA) to generate data collection instruments and a secure SQLserver database to provide storage and access services. SharePoint (Microsoft, Redmond, WA) was used as the study collaboration portal. A patient recruitment Web site was developed using Drupal (https://drupal.org/).
RESULTS
Subjects, Failure to Use Second Medication (RIS), and Dosage One hundred sixty-eight subjects (84 per treatment group) were randomized before starting Basic treatment (PT þ STIM). Figure 1 contains the Consolidated Standards of Reporting Trials diagram showing the disposition of subjects. Subject characteristics are listed in Table 1 . As would be expected for youth with DBDs, about 75% of the sample consisted of boys. 33 The large majority of the sample (73.8%) had ODD; the others had CD but would have qualified for ODD except for the CD pre-emption of diagnosis. IQ was virtually identical for the 2 groups, and most demographic variables were similar between groups. Household incomes were relatively low, and parental education (especially for fathers) was low. Thus, this sample largely comprised lower socioeconomic status families, although there was a significant minority from the middle class (Table 1) .
Fourteen subjects (3 from the Basic treatment group and 11 from the Augmented group) dropped out before completing the third week of the study, before the opportunity for adding the second drug. With the present analytic model, these participants did not appreciably affect the statistical outcomes. Eight subjects were clinical responders by the end of week 3 and did not take the second medication (3 from the Basic treatment group and 5 from the Augmented group). Thus, 22 subjects dropped out before they had an opportunity to benefit from Augmentation or were deemed not to need it. Treatment dropouts were generally lost to further follow-up. (Tables S1 and  S2 , available online, give details of all subject attrition).
The mean week 9 methylphenidate dose for the Basic group was 44.8 AE 14.6 mg/day compared with 46.1 AE 16.8 mg/day for the Augmented group (p ¼ .88). For the second drug, the subjects receiving PBO had a mean week 9 "dose" of 1.9 AE 0.72 mg/day compared with 1.7 AE 0.75 mg/day of RIS for those taking the active drug (Augmented; p ¼ .07).
Primary Outcome
The results for the NCBRF D-Total appear in Table 2 and Figure 2 . As determined by the Note: All 168 subjects were retained in the mixed model analysis regardless of whether they exited the study before week 9, failed to respond, or were clinical responders to Basic (parent training
a Although the second medication was dispensed, the subject was lost to follow-up with no week 4 assessments. linear mixed effects model, the group-by-time interaction was statistically significant (p ¼ .0016), indicating that the Augmented group D-Total scores decreased more over time than those in the Basic treatment group. At week 9, the difference between groups was statistically significant (p ¼ .0143), with an ES of 0.43. Using the change from week 3 to week 9, the ES was The p values, estimate (CI), and effect sizes represent results from square root transformation on specified NCBRF measurements. Table 2 ). A sensitivity analysis for ES was conducted by excluding those who never took the second drug (14 dropouts before week 3 and 8 PT þ STIM responders). The ES relative to BL was 0.51 and that relative to week 3 was 0.62.
(most ESs are listed in

Other NCBRF and ABS Outcomes
Findings for the other NCBRF and ABS variables are listed in Table 2 . The results for the PositiveSocial subscale of the NCBRF showed a significant group-by-time interaction (p ¼ .005): parents rated children with Augmented therapy as increasingly more socially competent than those with Basic treatment (ES ¼ 0.35 for BL to Week 9; ES ¼ 0.46 from week 3 to week 9). Analyses of the ABS showed no significant treatment effect for the Proactive subscale and a significant treatment-by-time effect for the Reactive subscale (p ¼ .0105, ES ¼ 0.29). Thus, Augmented treatment decreased reactive ("hot") aggression more than did Basic treatment, whereas treatment effects on proactive ("cold") aggression were not significantly different.
CGI and Responder Status
Endpoint CGI-I Scores. No significant difference was observed between groups on CGI-I scores at endpoint; within the Basic treatment group, 58 (70%) were "much or very much improved," 22 (26%) were minimally improved, and 3 (4%) were unchanged or worse. Within the Augmented treatment group, 63 (79%) were much/very much improved, 11 (14%) were minimally improved, and 6 (7%) were unchanged/worse (p ¼ .09). Similarly, no significant effect of RIS augmentation was observed on CGI-S. At the endpoint, for those receiving Basic treatment, 49 (59%) were rated as "normal/borderline/mildly ill" and 34 (41%) were "moderately/markedly/severely ill." For Augmented treatment, the figures were 56 (72%) and 22 (28%), respectively (p ¼ 
Adverse Events
No serious AEs related to study treatments were noted. Only AEs for weeks 4 to 9 (when the second medication was used) are presented in Table 3 . After subtracting the 22 subjects who were not given the second medication, AE data were available for 80 Basic treatment and 73 Augmented treatment participants. AEs occurring in at least 9 subjects per group are presented in Table 3 . Trouble falling asleep (p ¼ .02) was more common with the Basic treatment, whereas gastrointestinal upset (p ¼ .03) occurred more commonly in the Augmented group.
Abnormal Laboratory Test Results. There were 4 clinically significant abnormal values, 2 with RIS (triglyceride 389 mg/dL and prolactin 112 mg/L; the authors adopted the convention of reporting any prolactin level >100 as abnormal) and 2 with PBO (fasting glucose 144 mg/dL and fasting insulin 24 mIU/mL). The authors adopted the convention of reporting any prolactin level >100 as abnormal) and 2 with PBO (fasting glucose 144 and fasting insulin 24). Prolactin concentrations were analyzed at screening and at the endpoint for 77 children assigned to Basic treatment and 75 children assigned to Augmented treatment. Although the values were very similar at screening (5.7 AE 3.9 and 5.9 AE 3.0 mg/L, respectively), the values at endpoint were significantly different (Basic treatment 7.1 AE 9.3 mg/L, Augmented treatment 36.0 AE 27.5 mg/L; Wilcoxon ranked sum test, p < .0001). Using upper limits higher than 18.0 ng/mL for boys and higher than 30 ng/mL for girls, 46 of 68 children (68%) assigned to Augmented treatment had elevated prolactin levels compared with 4 of 73 (5%) assigned to Basic treatment. None were considered to be causing sexual or other AEs.
Weight. Mean weights (kilograms) AE SD for the 2 groups were as follows: Basic treatment: 33.2 AE 12.9 at BL and 32.0 AE 10.9 at week 9; Augmented treatment: 36.0 AE 14.5 at BL and 37.8 AE 15.5 at week 9 (F 8, 1311 , p < .0001). Body mass index (BMI) percentiles were 67.2 at BL and 56.5 at week 9 with Basic treatment and 66.6 at BL and 67.0 at week 9 with Augmented treatment (p < .0001). Thus, analysis of BMI data suggested that the weight gain in the Augmented treatment group was associated with overall growth, because the BMI percentile did not change appreciably over the course of the trial.
DISCUSSION
Three positive clinical findings resulted from this study. First, the primary outcome, NCBRF D-Total score, improved more with Augmented than with Basic treatment (ES ¼ 0.43 versus BL, 0.50 versus week 3, when need for further clinical improvement was determined and RIS or PBO was added). Second, there was a significant interaction on the ABS, with scores improving more on the Reactive subscale for Augmented than for Basic therapy, but not so on the Proactive subscale. Third, improvement on the Social Competence subscale of the NCBRF was significantly better with Augmented treatment. Conversely, clinician ratings of improvement on the CGI-I did not show a statistically significant advantage with Augmented treatment. Together, the findings indicate that RIS, when added to optimized PT þ STIM, provides a moderate advantage in parental ratings of disruptive behavior for children with serious aggression and additional disruptive behaviors. Note: Augmented ¼ parent training þ stimulant þ risperidone; basic ¼ parent training þ stimulant þ placebo. Sample size for each group excludes those who dropped out at or before week 3. One subject on basic treatment took medication from week 3 to 4 but did not return for assessment, resulting in 80 subjects. a Fisher exact test was used to compare the incidence of adverse events between groups.
The primary finding was not consistent with that of Armenteros et al., 15 who found no significant advantage for parent-rated aggression when RIS was added to the STIM. The inconsistency might be explained by differences in study design, choice of primary outcome measurement (the present study did not emphasize aggression per se), or severity of DBDs in study samples. The ESs (0.43 and 0.50) for Augmented treatment in this study were more modest than ESs of 0.82 and 0.75 reported by Aman et al. 11 and Snyder et al., 12 respectively. This study extends well beyond those investigations in terms of total exposure to intervention because all participants in the present study received 2 evidence-based treatments, PT þ STIM, before commencing PBO or RIS. In those previous studies, any STIM was maintained, but there was no effort to titrate it to optimal effect; no PT was provided; and the STIM effect was included in the BL score.
It is also interesting to compare CGI findings across studies. Aman et al. 11 reported 8% of the PBO group and 54% of the RIS group were much/very much improved. Snyder et al. 12 reported 6% of PBO and 48% of RIS subjects as much/very much improved. Conversely, in this trial, 70% of Basic treatment and 79% of Augmented treatment subjects were rated with CGI-I scores of 1 (very much improved) or 2 (much improved), with far more children benefiting from the overall treatment package provided in the present study. Indeed, the entry criteria in the present study were more exclusive (in terms of greater severity of aggressive behavior) compared with previous studies, which increased the opportunity for improvement for all children. In addition, marked benefits conferred by Basic treatment (PT þ STIM) were observed, even before RIS was added. Despite the nominal differential impact on the CGI, statistically significant improvement was observed on the NCBRF D-Total, NCBRF Social Competence, and ABS Reactive Aggression subscales. Hence, from the perspective of parent ratings, RIS produced better results than PBO. This is one of the first augmented treatment studies in child psychiatry, although augmented treatment has become widespread in practice. 5, 9 The question that naturally arises is whether such co-therapy is worth the added expense, inconvenience, and potential risks that may accompany the use of more than 1 drug. In attempting to answer this, it is important to keep in mind the following. First, RIS was added only after stimulant therapy was optimized and after PT was begun. Second, problem behavior, as assessed by the NCBRF D-Total, had decreased by approximately 42% by week 3. Indeed, the pre-post ES at week 3 for all participants was 1.25 for NCBRF D-Total and 0.81 for Social Competence, creating very substantial decreases overall before introducing augmentation. In a study of methylphenidate monotherapy in children with CD, 34 clinician ratings of improvement reached 68% (similar to the present control treatments), showing that stimulants often have robust effects on antisocial behavior. Third, even compared with the continuance of PT þ STIM for the last 6 weeks, Augmented therapy was of further benefit (about 21% additional decrease on the NCBRF D-Total, ES ¼ 0.50). Fourth, a meta-analysis of 45 randomized clinical trials targeting aggression in children found a mean ES of 0.56 for monotherapy. 35 As previously noted, the ESs for the present ITT sample when RIS was added to 2 other treatments were 0.43 (versus BL) and 0.50 (versus week 3), and the sensitivity ESs were 0.51 and 0.62, respectively. Further, DBDs, especially when accompanied by aggressive behavior, are often associated with severe later psychosocial problems and impairments such as substance abuse, sexual promiscuity, violent crime, accidents, depression, suicide attempts, spousal abuse, abusive parenting, and incarcerations, 36 making the price of ineffective treatment potentially very high (although continued treatment through childhood and adolescence is likely needed to affect long-term outcomes). Perhaps these findings will help to inform clinical decisions regarding the utility of short-term augmented treatment. They do not speak to the issue of medium-and longterm usefulness. The authors have exploratory moderator analyses planned for these data, which may better identify prime candidates for augmented treatment. They already have some indication that the risk-benefit ratio is more favorable for "hot" reactive aggression than for "cold" proactive aggression.
The finding of enhanced social competence is reassuring, suggesting that these participants were engaging in more socially appropriate behavior with Augmented treatment and that the treatment was not simply suppressing all behaviors, including those that are considered adaptive. Further, the observation of Augmented therapy having significantly greater effect on the ABS Reactive subscale than Basic treatment is in line with prevailing thought in the field. 37 This suggests that a principal mechanism of the drug effect is on the impulsive, unplanned disruptive actions of these children rather than on callous, planned aggression. As such, the findings help to verify a widely held clinical belief in the field for which there has been little empirical evidence one way or the other.
38 Figure 2 shows a trend for D-Total scores to converge after week 5 and diverge again by week 9. The authors were unable to find a potential cause for this observation, including attrition or any tendency of children receiving higher RIS doses to benefit less. PT was completed by week 9, and it may have contributed to the regained improvement at week 9.
Children receiving Augmented treatment gained more weight than those receiving Basic treatment. This appeared to be due more to subjects on Basic therapy losing weight than to subjects on Augmented therapy gaining weight. Indeed, the mean weight gain for the Augmented group was only 0.38 BMI percentile when using Centers for Disease Control and Prevention norms. As expected, there was a significant increase in prolactin concentrations with Augmented therapy (above the threshold of normal in 65% of cases); those increases were not associated with sexual side effects in this short study. Moreover, gastrointestinal upset was significantly greater with Augmented treatment (16.4% versus 5.0%). The authors are preparing a separate article to evaluate AEs in detail.
There were several limitations in this study. First, the authors were assessing a treatment strategy rather than a treatment combination per se. Consequently, when subjects dropped out or were found to be clinical responders in weeks 1 to 3, they did not contribute to the medication signal for participants assigned to Augmented treatment. Second, to alleviate subject burden, parent ratings on the NCBRF in weeks 1 and 2 were not required. This proved to be unfortunate because it prevented the authors from modeling the trajectory for participants who dropped out before week 3; hence, they did not fully benefit from the mixed effects regression model. An additional concern was the absence of a statistically significant advantage on CGI-I responder analysis. This finding might be explained by a lag or difference in clinician appreciation of improvements in overall functioning versus parent ratings of specific behaviors during a fairly short interval. It is also possible that group differences in dimensional scores of disruptive behavior are not translated into differences in overall functioning, perhaps decreasing any perceived added clinical benefit from RIS. In addition, the authors did not measure or control for parental psychopathology, which might have influenced the effect of PT; however, with 168 subjects, randomization should have distributed the effect of parental psychopathology evenly across groups.
Some of these limitations could obscure the signal from the addition of RIS, which showed a moderate statistical advantage compared with Basic treatment. Although many children with severe aggressive behavior benefit sufficiently from PT coupled with STIM, an important subgroup continues to experience a degree of behavioral dysregulation. The results of this study provide some reassurance that further behavioral benefit may be obtained from addition of RIS in cases in which there is a suboptimal response to first-line PT þ STIM, as per TRAAY guidelines. 19 It is important to note that these results were obtained with children selected for severity of aggression and disruptive behavior, and the risk-benefit ratio may well be decreased for children with milder disruptive behavior or no physical aggression.
The discrepancies between the a priori selected primary outcome variable (parent ratings of disruptive behavior) and the blinded clinician ratings of improvement warrant consideration by clinicians and clinical researchers. A common standard for clinical improvement is a CGI-I of 1 or 2, which in this study did not distinguish significantly between groups. Moreover, based on the authors' rigorous criteria for clinical responder (CGI-I score 1 and parent-rated D-Total score 15) after week 3, equal percentages of children in each group benefited from treatment at the endpoint (33.7% versus 34.2%), although there was a mean advantage of 13% for combined treatment for the intermediate weeks 4 through 8. The discrepancy in outcomes between the primary NCBRF D-Total and secondary CGI scores suggest that the blinded clinicians may have missed some important evidence of clinical benefit noted by parents. These discrepant results, observed in many studies, are difficult to interpret owing to complete confounding of reporter with measurement type. However, they do underscore the potential importance of not relying on one source of information when evaluating response to treatment in the clinical setting. Consistent with the present results, the TRAAY guidelines 19 recommend the use of standardized assessment instruments to help clinicians make more systematic and objective clinical decisions, especially when combined treatment is being considered. The present findings suggest that practicing clinicians may need to use similar rating scales to detect improvement.
In conclusion, the findings suggest that after showing marked improvements from behavior therapy and optimized STIM, children with DBD and ADHD who have continuing aggression and other disruptive behaviors can show further improvement with added RIS. Given the clinical severity of this child population, these findings provide evidence for an additional treatment should it be deemed necessary. It is important to emphasize, however, that these results are based on a relatively brief 6-week trial with possible subsequent waning of efficacy of RIS or the emergence of problematic AEs (e.g., weight gain and metabolic disturbance) and that the true implications of this study for informing clinical practice will be more fully realized when analyses of the 3-month follow-up assessment are completed. & 
